Sun Pharma defeats appeal over Otsuka’s injectable Abilify patent
Intellectual Property 2025-12-01 2:10 pm By Cindy Cameronne | Sydney
Please login to bookmark Close

The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au